Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immunogen Inc 830 WINTER ST WALTHAM MA 02451 USA

www.immunogen.com P: 781-895-0600

Description:

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla and in development programs of its partners Bayer, Biotest, CytomX, Novartis, Sanofi, Roche, Takeda, Debiopharm & Jazz Pharmaceuticals.'Among ImmunoGen's wholly owned candidates, mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, is being developed as a single-agent therapy for platinum-resistant ovarian cancer and in combination regimens for both platinum-resistant and platinum-sensitive disease. The candidate is also being developed in combination with other cancer drugs in a mid-stage study.'Pivekimab sunirine is currently under evaluation in early- to mid-stage studies for treatment of patients with acute myeloid leukemia & other CD123-positive hematological malignancies.

Key Statistics

Overview:

Market Capitalization, $K 8,315,425
Enterprise Value, $K 8,040,285
Shares Outstanding, K 266,264
Annual Sales, $ 108,780 K
Annual Net Income, $ -222,930 K
Last Quarter Sales, $ 113,430 K
Last Quarter Net Income, $ 30,750 K
EBIT, $ -80,000 K
EBITDA, $ -78,220 K
60-Month Beta 1.18
% of Insider Shareholders 5.07%
% of Institutional Shareholders 90.50%
Float, K 252,764
% Float 94.93%
Short Volume Ratio 0.34

Growth:

1-Year Return 641.81%
3-Year Return 196.58%
5-Year Return 452.74%
5-Year Revenue Growth -5.78%
5-Year Earnings Growth -17.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.10 on 11/02/23
Next Earnings Date 03/06/24
Earnings Per Share ttm -0.31
EPS Growth vs. Prev Qtr 600.00%
EPS Growth vs. Prev Year 132.26%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

IMGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 83.37
Price/Earnings to Growth N/A
Return-on-Equity % -22.11%
Return-on-Assets % -13.53%
Profit Margin % -204.94%
Debt/Equity 0.13
Price/Sales 28.51
Price/Cash Flow N/A
Price/Book 14.81
Book Value/Share 2.11
Interest Coverage -52.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar